gMendel® announces two new Board members.

May 29, 2023, Copenhagen – gMendel® announced today the appointment of Prof. Deepak Asudani and Dr. Zoran Zdraveski, to the Board of Directors, effective immediately. The current board is composed of four members and is led by Lars Staal Wegner, Chair. The appointments come as gMendel® works to expand its diagnostic technology to the 33 most prevalent genetic disorders, worldwide.

“We look forward to the guidance of our new members, who will help gMendel® continue to grow and meet so-far-unmet clinical needs for better, faster, and affordable diagnosis of a wide range of genetic disorders”, said Chris Kyriakidis, CEO and co-founder of gMendel. “They bring with them a wealth of experience and a deep understanding of our mission, which will be invaluable as we continue to innovate and expand our products and technology”.

Deepak is a highly accomplished medical doctor and academic clinician with over 20 years of experience, caring for patients in various clinical settings. He has a wealth of knowledge in healthcare policies, regulations, and operations, including quality improvement, protocol development, finance, and compensation. He possesses a diverse skill set that includes expertise in precision medicine, pharmacogenomics, emergency disaster management, global health, and STEM education. Deepak is a Certified Physician Executive, known for his analytical skills, pragmatic approach, and result-oriented communication style. He completed his medical residency and public health training at New York Medical College and the University of Massachusetts and has leadership training from Harvard Kennedy School of Government and the University of California, San Diego. Additionally, he holds certifications in Genetics and Genomics from Stanford University and as a Director from the National Association of Corporate Directors.

Zoran Zdraveski, J.D., Ph.D., boasts over two decades of experience in legal, intellectual property, and business operations within the biopharmaceutical industry. Currently, Zoran serves as the Chief Legal Officer at Tscan Therapeutics. Prior to joining Tscan, Zoran held the position of Chief Legal and Technology Operations Officer at Magenta Therapeutics Inc., where he established the legal team and oversaw all legal, intellectual property, and compliance matters, both before and after the company’s initial public offering in 2018. Zoran’s previous experience also includes serving as Vice President and Associate General Counsel at Epizyme Inc. and holding patent counsel positions at Ironwood and Genzyme Therapeutics. Zoran’s educational background includes an M.S. in Chemistry and a B.F.A. and B.A. in Art and Chemistry from Southern Methodist University, a J.D. from Suffolk University Law School, and a Ph.D. in Biochemistry from the Massachusetts Institute of Technology.

Download the press release.

About gMendel®

gMendel® is a Danish medical innovation growth company that aims to transform the diagnosis of genetic disorders for better disease management. gMendel® applies rigorous science and does tireless research to develop medical technology solutions that will help patients live longer and better. The gMendel® technology combines genomics, artificial intelligence and blockchain technology to provide a shorter, safer and more cost-effective path to accurate diagnosis and potential treatment, ensuring the highest security and encryption of patient data. gMendel®’s products and services accelerate the diagnosis journey and advance inclusion, diversity and equity in care and treatment.